New PET scan may predict breast cancer drug success
NCT ID NCT02226276
First seen Feb 16, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This small pilot study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug ado-trastuzumab emtansine (T-DM1). Ten women with cancer that had spread to other parts of the body received the scan before treatment. The goal was to see if the scan's images could tell doctors who would benefit from the drug, helping avoid unnecessary side effects for those unlikely to respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.